- Rationale for Immune Checkpoint Inhibitors and Optimizing Treatments for Recurrent or Metastatic HNSCC
- Practical Guidance for Clinical Integration of Immune Checkpoint Inhibitors
- Future Directions for Immuno-Oncology in HNSCC
- Closing remarks
Date / Time
Barbara Ann Burtness, MD
Professor of Medicine
Yale University School of Medicine
Co-Leader, Developmental Therapeutics Program
Yale Cancer Center
New Haven, Connecticut
Cristina Rodriguez, MD
Department of Medicine
University of Washington
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating immunotherapy into the treatment of patients with head and neck cancer.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers and their patients with HNSCC.
Upon completion of this activity, participants should be able to:
- Gain insight on the role of the immune system and immune escape in HNSCC, along with the mechanisms of action of different immune modulatory agents
- Plan therapeutic strategies for patients with recurrent or metastatic HNSCC that has progressed on or after platinum-containing chemotherapy
- Evaluate the latest science and clinical trial results of immune checkpoint inhibitors in adjuvant and neoadjuvant settings and alone or in combination with radiotherapy or biotherapy across all indications
- Identify patients that would benefit from immunotherapy based on optimal assessment of predictive biomarkers
- Manage immune-related toxicities associated with immune checkpoint inhibitors in patients with HNSCC
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Pharmacist Continuing Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-19-044-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.